Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v2-FR
Language English French
Date Updated 2020-02-13 2017-03-13
Drug Identification Number 02230805 02230805
Brand name TEVA-TERAZOSIN TEVA-TERAZOSIN
Common or Proper name TERAZOSIN TERAZOSIN
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients TERAZOSIN HCL TERAZOSIN HCL
Strength(s) 1MG 1MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 100 100
ATC code G04CA G04CA
ATC description DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2014-03-07 2014-03-07
Estimated end date 2022-12-01 Unknown
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments